Linezolid

Concomitant use contraindicated. Serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, and autonomic instability reported with MAOIs like linezolid.

MAOI-like interaction may manifest as serotonin syndrome or opioid toxicity. Use not recommended; avoid within 14 days of stopping treatment.

Reversible MAOI that increases risk of serotonin syndrome when started with buspirone.

Reversible MAOI; starting buspirone is contraindicated due to increased risk of serotonin syndrome.

Concomitant use increases risk of serotonin syndrome. Citalopram is contraindicated in patients taking linezolid.

Concomitant use increases risk of serotonin syndrome. Citalopram is contraindicated in patients taking linezolid.

Concomitant use increases risk of serotonin syndrome. Contraindicated due to MAOI-like activity.

Concomitant use increases risk of serotonin syndrome. Contraindicated in patients being treated with linezolid.

Concomitant use is contraindicated due to increased risk of serotonin syndrome.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

Linezolid is an MAOI. Concomitant use with doxepin hydrochloride increases risk of serotonin syndrome. Use within 14 days of discontinuation is contraindicated.

Concomitant use should be avoided due to potential for increased blood pressure.

Concomitant use increases risk of serotonin syndrome. Use of linezolid with duloxetine or within 5 days of stopping duloxetine is contraindicated.

MAOI with potential to increase serotonin syndrome risk. Escitalopram is contraindicated in patients taking linezolid.

Concomitant use increases risk of serotonin syndrome. Escitalopram oxalate is contraindicated in patients taking linezolid.

Concomitant use increases risk of serotonin syndrome. GEPIRONE is contraindicated in patients taking linezolid or within 14 days of stopping.

Not recommended for patients taking MAOIs or within 14 days of stopping. May manifest as serotonin syndrome or opioid toxicity.

MAOI-like antibiotic that increases risk of serotonin syndrome when used with levomilnacipran. Contraindicated use.

Meperidine is contraindicated in patients receiving MAOIs. Can cause unpredictable, severe, and occasionally fatal reactions including coma, respiratory depression, serotonin syndrome, convulsions, and hypertension.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, and other serious complications.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure.

Avoid use with midodrine.

Do not initiate SAVELLA in patients being treated with linezolid. Discontinue SAVELLA before initiating linezolid treatment.

Concomitant use increases risk of serotonin syndrome. Mirtazapine is contraindicated in patients taking this MAOI.

Linezolid is a reversible, nonselective inhibitor of monoamine oxidase and is contraindicated with MAOIs due to potential serious interactions.

MAOI activity may cause serotonin syndrome or opioid toxicity; do not use morphine in patients taking linezolid or within 14 days of stopping.

MAOI not recommended; use contraindicated within 14 days of stopping. Can manifest as serotonin syndrome or opioid toxicity.

MAOI-like interaction may result in serotonin syndrome or opioid toxicity.

Concomitant use increases risk of serotonin syndrome. Paroxetine is contraindicated in patients taking linezolid.

Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.

Concomitant use is contraindicated as linezolid is an MAOI with potential for serotonin syndrome.

Potent MAO inhibitor with reversible nonselective MAO inhibition activity; co-administration increases risk of nonselective MAO inhibition leading to hypertensive crisis.

Contraindicated due to increased risk for hypertensive crisis; linezolid has reversible nonselective MAO inhibition activity.

Concomitant use increases risk of serotonin syndrome. Sertraline is contraindicated in patients taking MAOIs including linezolid.

Concomitant use of MAOI linezolid with sertraline hydrochloride increases risk of serotonin syndrome.

MAOI activity may cause serotonin syndrome or opioid toxicity. Do not use or within 14 days of stopping.

Contraindicated; emergency use only with close monitoring and immediate discontinuation of tranylcypromine if necessary.

Contraindicated agent. If emergency treatment necessary, discontinue tranylcypromine immediately and monitor closely for adverse reactions.

Concomitant use increases risk of serotonin syndrome. Trazodone is contraindicated with linezolid and intravenous methylene blue.

Concomitant use with linezolid (an MAOI) increases the risk of serotonin syndrome and is contraindicated.

MAOI with properties that increase risk of serotonin syndrome when used with venlafaxine. Contraindicated.

Concomitant use with linezolid (MAOI) increases risk of serotonin syndrome. Contraindicated in patients taking linezolid.

MAOI that increases risk of serotonin syndrome when combined with vilazodone hydrochloride.

Concomitant use increases risk of serotonin syndrome. Contraindicated with linezolid or within 21 days of stopping vortioxetine.

Linezolid has potential for interaction with adrenergic agents; monitoring and caution required.

Inhibition of MAO prolongs and potentiates dopamine effects, potentially resulting in severe hypertension and cardiac arrhythmia.

Combining linezolid with fluoxetine can precipitate serotonin syndrome (agitation, hyperthermia, rigidity, autonomic instability). Fluoxetine's long half-life means the risk persists for weeks after it is stopped; a washout period is generally required before linezolid is given.

MAO inhibitor activity may result in serotonin syndrome; carefully observe patient during treatment initiation and dose adjustment.

Concomitant use has resulted in serotonin syndrome.

Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dosage modification; discontinue metaxalone if serotonin syndrome occurs.

Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.

Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if norepinephrine bitartrate cannot be avoided.

Concomitant use has resulted in serotonin syndrome. Carefully observe patient during treatment initiation and dose adjustment.

MAOI activity may result in serotonin syndrome or opioid toxicity.

MAO inhibitor activity may result in serotonin syndrome; monitor regularly during initiation and dose adjustment.

Strong CYP3A4 inducer that could cause similar or smaller decrease in linezolid exposure as rifampin.

Strong CYP3A4 inducer that could cause similar or smaller decrease in linezolid exposure as rifampin.

Strong CYP3A4 inducer that could cause similar or smaller decrease in linezolid exposure as rifampin.

Co-administration of rifampin with linezolid resulted in 21% decrease in linezolid Cmax and 32% decrease in linezolid AUC. Clinical significance is unknown.